FDA Wants Your Data to Tweak Over-the-Counter Rules
Published Date: 7/16/2026
Notice
Summary
The FDA is rolling out a clear process to ask the public for data to help update rules about over-the-counter (OTC) drugs. This means anyone interested in OTC drug safety and use can share info that might change how these medicines are regulated. The new process starts now and aims to make drug updates smarter and faster, with no direct costs to the public but big benefits for safer medicines.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Public data submissions for OTC monographs
Starting July 16, 2026, FDA will announce Data Requests on the OTC Monographs@FDA portal (https://www.accessdata.fda.gov/scripts/cder/omuf/). The public may submit data and information in response to those Data Requests to help inform certain future over‑the‑counter (OTC) monograph drug activities.
Submission confidentiality and notification process
Each Data Request will include instructions on how to submit data, how confidential information will be handled, and how submissions may be viewed by the public. FDA also intends to list planned Data Requests in its Annual Forecast for Planned Monograph Activities (a nonbinding 3‑year list) and offers an email mailing list on the OTC Monographs@FDA portal for alerts.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14438 — Agency Information Collection Activities; Proposed Collection; Comment Request; Infant Formula Requirements
The FDA wants your thoughts on how they collect info about infant formula rules, like labeling, quality checks, and recordkeeping. This affects infant formula makers who must follow these rules and use a new electronic form to report info. You’ve got until September 15, 2026, to share your comments—no cost changes yet, just a chance to improve how info is gathered!
2026-14441 — Agency Information Collection Activities; Proposed Collection; Comment Request; Accreditation Scheme for Conformity Assessment Program
The FDA wants your thoughts on a plan to improve how they check if medical products meet safety rules. This affects companies making medical devices and could change how they prove their products are safe. You’ve got until September 15, 2026, to share your ideas—no cost changes yet, just a chance to help shape the process!
2026-14436 — Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Devices; Voluntary Improvement Program
The FDA wants your thoughts on a new plan to collect info from medical device makers who join a Voluntary Improvement Program. This program aims to help companies improve their devices without extra paperwork stress. If you’re involved in making or managing medical devices, you’ve got until September 15, 2026, to share your feedback—no fees, just your voice!
2026-14434 — Agency Information Collection Activities; Proposed Collection; Comment Request; Requirements for Cosmetic Products
The FDA wants your thoughts on new info they might collect about cosmetic products. This affects companies making or selling cosmetics, who may need to share more details soon. You’ve got until September 15, 2026, to send in your comments—no cost yet, just your voice!
Previous / Next Documents
Previous: 2026-14280 — Importer of Controlled Substances Application: Catalent CTS, LLC
Catalent CTS, LLC wants to become an official importer of certain controlled substances like marijuana and gamma hydroxybutyric acid. People and companies involved can share their thoughts or ask for a hearing by August 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or changes for the public are mentioned yet.
Next: 2026-14284 — Bulk Manufacturer of Controlled Substances Application: AMPAC Fine Chemicals LLC
AMPAC Fine Chemicals LLC wants to become a big-time maker of certain controlled drugs like amphetamine and methylphenidate. This means they’ll handle large amounts of these substances, which are mostly used in medicines. People and companies can share their thoughts or ask for a hearing by September 14, 2026, so don’t miss the deadline!